A single dose of Pfizer’s coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with Covid-19, according to a UK study published on April 30.
Covid-19 vaccines deployed in England can cut transmission of the coronavirus in households by up to a half, data from Public Health England (PHE) showed on April 28, in addition to the protection the shots offer against symptomatic infection.
The U.S. Food and Drug Administration placed a clinical hold on KalVista Pharmaceuticals’ proposed Phase II trial of KVD824, a prophylactic treatment of hereditary angioedema. The regulatory agency requested additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial.
The first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.
Treating Covid-19 patients at home with a commonly used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on April 12 which doctors said could change the way the disease is treated around the world.
McCann Health on April 7 announced two key appointments to its leadership team in Europe: Saturnino Izquierdo has taken on an expanded role of President, Europe and LATAM and Jonathan Kukathasan was promoted to President, UK, McCann Health.
Coronavirus-related deaths worldwide crossed 3 million on April 6, according to a Reuters tally, as the latest global resurgence of Covid-19 infections is challenging vaccination efforts across the globe.
Novavax Inc. said on April 5 participants in the company’s Covid-19 vaccine trials in South Africa and the UK can receive additional shots, ensuring those who received a placebo can also get the active vaccine.
Britain on March 22 demanded the European Union allow the delivery of Covid-19 vaccines the country has ordered as tensions over a possible export ban on EU-manufactured shots mounted and Brussels pointed an accusing finger at drugmaker AstraZeneca.
The U.S. Federal Trade Commission (FTC) formed a multinational working group to evaluate pharmaceutical mergers.
